The objective of this meta-analysis was to examine the impact of the GLP-1 RA on renal function parameters in randomized controlled trials.A systematic search was performed in PubMed-MEDLINE, Scopus, Web of Science, ClinicalTrials.gov, and Google Scholar databases. Meta-analysis was performed using a random-effects model and sensitivity analysis.Data from 18 randomized controlled trials involving 12,192 subjects, showed that treatment with GLP-1 RA had no effect on serum creatinine levels (WMD: 0.00 mg/mL, 95% CI: -0.01, 0.01, p = 0.83, I2 = 0%) and glomerular filtration rate (WMD: 1.01 mL/min/1.73 m2 , 95% CI: -1.61, 3.63, p = 0.45, I2 = 75%). On the other hand, a significant reduction in urinary albumin excretion (WMD: -18.01 mg/day, 95% CI: -31.20, -4.82, p = 0.007, I2 = 23%) and albumin to creatinine ratio (WMD: -6.74 mg/g, 95% CI: -12.64, -0.85, p = 0.03, I2 = 68%) was detected after GLP-1 RA therapy.Results of our meta-analysis revealed that GLP-1 RA treatment decreases urinary albumin excretion and albumin to creatinine ratio but it did not cause significant changes in creatinine levels and glomerular filtration rate.This article is protected by copyright. All rights reserved.